Statins and the liver

Cynthia Herrick; Samira Bahrainy; Edward A. Gill

doi:10.1016/j.ccl.2015.02.005

Statins and the liver

Cynthia Herrick, Samira Bahrainy, Edward A. Gill

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Lipid lowering, particularly with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors ("statins"), reduces the risk of cardiovascular disease. Patients with chronic liver disease present challenges to the use of lipid medications. In the case of most liver disorders, the concern has been one of safety. There is evidence that most lipid-lowering medications can be used safely in many situations, although large outcomes trials are lacking. This review examines lipid physiology and cardiovascular risk in specific liver diseases and reviews the evidence for lipid lowering and the use of statins in chronic liver disease.

Original language	English
Pages (from-to)	257-265
Number of pages	9
Journal	Cardiology clinics
Volume	33
Issue number	2
DOIs	https://doi.org/10.1016/j.ccl.2015.02.005
State	Published - May 1 2015

Keywords

Chronic liver disease
Dyslipidemia
Hepatic transaminases
Statins

Access to Document

10.1016/j.ccl.2015.02.005

Cite this

@article{7557ae37e5924518b3708bfa7f480ded,

title = "Statins and the liver",

abstract = "Lipid lowering, particularly with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors ({"}statins{"}), reduces the risk of cardiovascular disease. Patients with chronic liver disease present challenges to the use of lipid medications. In the case of most liver disorders, the concern has been one of safety. There is evidence that most lipid-lowering medications can be used safely in many situations, although large outcomes trials are lacking. This review examines lipid physiology and cardiovascular risk in specific liver diseases and reviews the evidence for lipid lowering and the use of statins in chronic liver disease.",

keywords = "Chronic liver disease, Dyslipidemia, Hepatic transaminases, Statins",

author = "Cynthia Herrick and Samira Bahrainy and Gill, {Edward A.}",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

month = may,

day = "1",

doi = "10.1016/j.ccl.2015.02.005",

language = "English",

volume = "33",

pages = "257--265",

journal = "Cardiology clinics",

issn = "0733-8651",

number = "2",

}

TY - JOUR

T1 - Statins and the liver

AU - Herrick, Cynthia

AU - Bahrainy, Samira

AU - Gill, Edward A.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Lipid lowering, particularly with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors ("statins"), reduces the risk of cardiovascular disease. Patients with chronic liver disease present challenges to the use of lipid medications. In the case of most liver disorders, the concern has been one of safety. There is evidence that most lipid-lowering medications can be used safely in many situations, although large outcomes trials are lacking. This review examines lipid physiology and cardiovascular risk in specific liver diseases and reviews the evidence for lipid lowering and the use of statins in chronic liver disease.

AB - Lipid lowering, particularly with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors ("statins"), reduces the risk of cardiovascular disease. Patients with chronic liver disease present challenges to the use of lipid medications. In the case of most liver disorders, the concern has been one of safety. There is evidence that most lipid-lowering medications can be used safely in many situations, although large outcomes trials are lacking. This review examines lipid physiology and cardiovascular risk in specific liver diseases and reviews the evidence for lipid lowering and the use of statins in chronic liver disease.

KW - Chronic liver disease

KW - Dyslipidemia

KW - Hepatic transaminases

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84928815727&partnerID=8YFLogxK

U2 - 10.1016/j.ccl.2015.02.005

DO - 10.1016/j.ccl.2015.02.005

M3 - Review article

C2 - 25939298

AN - SCOPUS:84928815727

SN - 0733-8651

VL - 33

SP - 257

EP - 265

JO - Cardiology clinics

JF - Cardiology clinics

IS - 2

ER -

Statins and the liver

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this